Gilead Sciences (LIM:GILD) Cash And Cash Equivalents : $6,085 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Gilead Sciences Cash And Cash Equivalents?

Gilead Sciences's quarterly cash and cash equivalents increased from Jun. 2023 ($5,704.00 Mil) to Sep. 2023 ($5,705.00 Mil) and increased from Sep. 2023 ($5,705.00 Mil) to Dec. 2023 ($6,085.00 Mil).

Gilead Sciences's annual cash and cash equivalents increased from Dec. 2021 ($5,338.00 Mil) to Dec. 2022 ($5,412.00 Mil) and increased from Dec. 2022 ($5,412.00 Mil) to Dec. 2023 ($6,085.00 Mil).

Gilead Sciences Cash And Cash Equivalents Historical Data

The historical data trend for Gilead Sciences's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Cash And Cash Equivalents Chart

Gilead Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

11,631.00

5,997.00

5,338.00

5,412.00

6,085.00

Gilead Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															5,412.00	4,936.00	5,704.00	5,705.00	6,085.00

Gilead Sciences Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Gilead Sciences (LIM:GILD) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Gilead Sciences Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (LIM:GILD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (LIM:GILD) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.